DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy.
- DOI
- 10.3389/fimmu.2023.1197053
- Published
- 2023
- Container
- Frontiers in immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2023.1197053,
title = {DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy.},
author = {Cifaldi L and Melaiu O and Giovannoni R and Benvenuto M and Focaccetti C and Nardozi D and Barillari G and Bei R},
year = {2023},
journal = {Frontiers in immunology},
doi = {10.3389/fimmu.2023.1197053},
url = {https://doi.org/10.3389/fimmu.2023.1197053}
}RIS
TY - JOUR TI - DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy. AU - Cifaldi L AU - Melaiu O AU - Giovannoni R AU - Benvenuto M AU - Focaccetti C AU - Nardozi D AU - Barillari G AU - Bei R PY - 2023 JO - Frontiers in immunology DO - 10.3389/fimmu.2023.1197053 UR - https://doi.org/10.3389/fimmu.2023.1197053 ER -
APA
L, C., O, M., R, G., M, B., C, F., D, N., G, B., & R, B. (2023). DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2023.1197053
Source records
- pubmed · retrieved 2026-11-10T18:52:26.549Z